SURGE
1 known investors
Find your way into SURGE
942 people in our graph share verified history with the SURGE team — schools, employers, funds. One of them is your warm intro.
Kyle Dohertyunlockedknows Michael Goldberg · together at Massachusetts Institute of Technology (overlapped)
×4knows the team · via Massachusetts Institute of Technology
×4knows the team · via University of Cambridge
×2knows the team · via Harvard Medical School
knows the team · via Dana-Farber Cancer Institute
SURGE develops clinical approaches for cancer immunotherapy and post-surgical cancer recurrence prevention. The company applies bioengineering and drug delivery innovations to address unmet oncology needs.
Founders & leadership
MG
Michael GoldberginCEOMichael Goldberg previously conducted research in academic settings with publications in top-tier journals including Cell, Nature, and Science. He is now CEO of SURGE, which develops localized drug delivery approaches for cancer immunotherapy during surgical tumor resection.
Investors · 1
Frequently asked questions
- What does SURGE do?
- SURGE develops clinical approaches for cancer immunotherapy and post-surgical cancer recurrence prevention. The company applies bioengineering and drug delivery innovations to address unmet oncology needs.
- Who are SURGE's investors?
- SURGE's investors include Intuitive Ventures.